ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2012
Macrophage killing of bacterial and fungal pathogens is not inhibited by intense intracellular accumulation of the lipoglycopeptide antibiotic oritavancin.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Extrapolation of oritavancin PK/PD targets to inform therapeutic drug monitoring: a systematic review.The Journal of antimicrobial chemotherapy · 2026Pooled it
- What Place Is There for Long-Acting Antibiotics in the Management of Gram-Positive Infections? A Qualitative Cross-Sectional Study.Antibiotics (Basel, Switzerland) · 2024Article
- A protein-free vaccine stimulates innate immunity and protects against nosocomial pathogens.Science translational medicine · 2023Article
- The Clinical Efficacy of Multidose Oritavancin: A Systematic Review.Antibiotics (Basel, Switzerland) · 2023Review
- The role of long-acting antibiotics in the clinical practice: a narrative review.Le infezioni in medicina · 2023Review
- Monoclonal Antibody Therapy againstInfection and immunity · 2021Article
- Clinical and Microbiological Characteristics of Candida guilliermondii and Candida fermentati.Antimicrobial agents and chemotherapy · 2018Article
- Oritavancin (Orbactiv): A New-Generation Lipoglycopeptide for the Treatment Of Acute Bacterial Skin and Skin Structure Infections.P & T : a peer-reviewed journal for formulary management · 2018Article
- Monoclonal Antibody Protects Against Acinetobacter baumannii Infection by Enhancing Bacterial Clearance and Evading Sepsis.The Journal of infectious diseases · 2017Article
- Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.Drugs · 2015Review
- Oritavancin Pharmacokinetics and Bone Penetration in Rabbits.Antimicrobial agents and chemotherapy · 2015Article
- Oritavancin for acute bacterial skin and skin structure infections.Expert opinion on pharmacotherapy · 2015Review
- Profile of oritavancin and its potential in the treatment of acute bacterial skin structure infections.Infection and drug resistance · 2015Review
- Antibacterial responses of retinal Müller glia: production of antimicrobial peptides, oxidative burst and phagocytosis.Journal of neuroinflammation · 2014Article
- Study of macrophage functions in murine J774 cells and human activated THP-1 cells exposed to oritavancin, a lipoglycopeptide with high cellular accumulation.Antimicrobial agents and chemotherapy · 2014Article
- Influence of the protein kinase C activator phorbol myristate acetate on the intracellular activity of antibiotics against hemin- and menadione-auxotrophic small-colony variant mutants of Staphylococcus aureus and their wild-type parental strain in human THP-1 cells.Antimicrobial agents and chemotherapy · 2012Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
Intact phagocytic effector function is fundamental to host defense against microbial pathogens. Concern has been raised regarding the potential that accumulation of certain agents, including cationic amphiphilic antibiotics, within macrophages could cause a mixed-lipid storage disorder, resulting in macrophage dysfunction in recipients. The ability of 2 macrophage cell lines (HL-60; RAW 264.7) to kill archetypal Gram-positive (Staphylococcus aureus), Gram-negative (Acinetobacter baumannii), and fungal (Candida albicans) pathogens was tested following exposure of the macrophages to the lipoglycopeptide antibiotic oritavancin. Oritavancin did not affect killing of C. albicans but markedly enhanced killing of S. aureus by both macrophages. Oritavancin modestly reduced killing of A. baumannii by HL-60 cells but not by RAW 264.7 cells. Thus, macrophage killing of microbes remains intact despite substantial intracellular accumulation with a lipoglycopeptide antibiotic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.